Dr. Tanya S. Schreibman, MD

Dr. Schreibman practices at Can Community Health, Inc. in Sarasota, Florida.

Dr. Schreibman's NPI, 1609877190, was assigned on August 9, 2005. Dr. Schreibman graduated from Weill Cornell Medicine in 1997. Dr. Schreibman holds Florida license ME90796.

Dr. Schreibman's primary practice is Can Community Health, Inc., at 1231 N Tuttle Ave, Sarasota, FL 34237 in Sarasota County. The practice phone is (941) 366-0134.

Dr. Schreibman's primary practice is Can Community Health, Inc. in Sarasota, Florida. Dr. Schreibman is also affiliated with Sarasota Memorial Hospital - Sarasota Campus. The medical group on file is CAN Community Health. Dmand AI also links Dr. Schreibman to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Schreibman practices, 3 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Schreibman's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Schreibman is board certified in infectious disease by the American Board of Internal Medicine. Dmand AI has Dr. Schreibman's licenses on file in 2 states: Florida and Connecticut.

Dmand AI lists hiv/aids among the conditions Dr. Schreibman treats.

CMS data shows 293 Medicare services from Dr. Schreibman across 2 procedure codes in 2024, for 79 Medicare patients. Medicare paid $14,022 for them. Every service was in an office.

CMS counts 79 Medicare patients who saw Dr. Schreibman in 2024. The largest group is 65 to 74, with 35 patients. 70% of them have high cholesterol, and 66% have high blood pressure. 37% are also on Medicaid. Their average risk score is 1.18, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Schreibman's median patient age at 60, with 17% women.

In 2024, Dr. Schreibman wrote 6,352 Medicare Part D claims for 189 patients. 60% of them were for generic drugs. CMS names the drug for 5,944 of them, across 97 drugs with 11 or more claims each, at $7,324,098 in total drug cost. In 2023, CMS named 5,919 claims across 103 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Schreibman for performance year 2024, reported as part of a group. Dr. Schreibman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Schreibman as offering telehealth.

Dmand AI links 4 papers to Dr. Schreibman, published from 2003 to 2025. 2003 was the busiest year, with 2. The most frequent topics are HIV Infections and Chemoprevention. Dr. Schreibman has published most often in Clin Infect Dis. Dr. Schreibman's most frequent co-authors are Ellen Eaton, MD and Claudia T. Martorell, MD.

Dmand AI links Dr. Schreibman to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Acquired Immunodeficiency Syndrome, HIV Infections and Lentivirus Infections.

CMS Open Payments shows 289 general payments to Dr. Schreibman from 12 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 79% of the total. ViiV Healthcare Company paid the most, $2,112. It also lists 6 research payments totaling $437 in 2017.

Dr. Schreibman graduated from Weill Cornell Medicine in 1997.

Dr. Schreibman is in network with 20 carriers, including Elevance, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 11. Check the plan with the practice before a visit.